{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T13:47:14Z","timestamp":1748267234293,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T00:00:00Z","timestamp":1631318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T00:00:00Z","timestamp":1631318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Novartis Pharma KK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12185-021-03216-5","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T03:27:26Z","timestamp":1631330846000},"page":"33-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow\u2011up of the Japanese subgroup of the randomized ENESTnd trial"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4203-990X","authenticated-orcid":false,"given":"Hirohisa","family":"Nakamae","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Maki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,11]]},"reference":[{"issue":"6","key":"3216_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691\u2013709.","journal-title":"Am J Hematol"},{"issue":"1","key":"3216_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-019-0729-2","volume":"12","author":"S Soverini","year":"2019","unstructured":"Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019;12(1):39.","journal-title":"J Hematol Oncol"},{"key":"3216_CR3","unstructured":"National Comprehensive Cancer Network. NCCN: Clinical practice guidelines in oncology. Chronic Myeloid Leukemia V3.2021. 2021."},{"issue":"5","key":"3216_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561\u20136.","journal-title":"Nat Med"},{"issue":"1","key":"3216_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","volume":"9","author":"J Zhang","year":"2009","unstructured":"Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9(1):28\u201339.","journal-title":"Nat Rev Cancer"},{"key":"3216_CR6","unstructured":"ClinicalTrials.gov. A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd). Accessed 15 July 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00471497"},{"issue":"2","key":"3216_CR7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440\u201353.","journal-title":"Leukemia"},{"issue":"24","key":"3216_CR8","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"3216_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u201354.","journal-title":"Leukemia"},{"issue":"5","key":"3216_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12185-011-0841-8","volume":"93","author":"H Nakamae","year":"2011","unstructured":"Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, et al. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. Int J Hematol. 2011;93(5):624\u201332.","journal-title":"Int J Hematol"},{"issue":"3","key":"3216_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12185-017-2353-7","volume":"107","author":"H Nakamae","year":"2018","unstructured":"Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, et al. Nilotinib vs imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2018;107(3):327\u201336.","journal-title":"Int J Hematol"},{"issue":"7","key":"3216_CR12","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3324\/haematol.2013.091272","volume":"99","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, et al. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 2014;99(7):1204\u201311.","journal-title":"Haematologica"},{"issue":"29","key":"3216_CR13","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315\u201381.","journal-title":"Eur Heart J"},{"issue":"25","key":"3216_CR14","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25):2889\u2013934 (Pt B).","journal-title":"J Am Coll Cardiol"},{"key":"3216_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2337\/dc19-S002","volume":"42","author":"American Diabetes A","year":"2019","unstructured":"American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:13\u201328 (Suppl 1).","journal-title":"Diabetes Care"},{"issue":"4","key":"3216_CR16","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"20","key":"3216_CR17","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3216_CR18","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12185-017-2208-2","volume":"105","author":"H Nakamae","year":"2017","unstructured":"Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, et al. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol. 2017;105(6):792\u2013804.","journal-title":"Int J Hematol"},{"issue":"1","key":"3216_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12185-020-02878-x","volume":"112","author":"M Hino","year":"2020","unstructured":"Hino M, Matsumura I, Fujisawa S, Ishizawa K, Ono T, Sakaida E, et al. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia. Int J Hematol. 2020;112(1):24\u201332.","journal-title":"Int J Hematol"},{"issue":"10","key":"3216_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/ajh.23788","volume":"89","author":"C Gambacorti-Passerini","year":"2014","unstructured":"Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014;89(10):947\u201353.","journal-title":"Am J Hematol"},{"issue":"5","key":"3216_CR21","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(5):612\u201321.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3216_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino Sr","year":"2008","unstructured":"D\u2019Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117(6):743\u201353.","journal-title":"Circulation"},{"key":"3216_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/VHRM.S108874","volume":"13","author":"N Aghel","year":"2017","unstructured":"Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017;13:293\u2013303.","journal-title":"Vasc Health Risk Manag"},{"issue":"3","key":"3216_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2337\/diacare.29.03.06.dc05-1637","volume":"29","author":"SH Wild","year":"2006","unstructured":"Wild SH, Byrne CD, Smith FB, Lee AJ, Fowkes FG. Low ankle-brachial pressure index predicts increased risk of cardiovascular disease independent of the metabolic syndrome and conventional cardiovascular risk factors in the Edinburgh artery study. Diabetes Care. 2006;29(3):637\u201342.","journal-title":"Diabetes Care"},{"issue":"24","key":"3216_CR25","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1161\/CIR.0b013e318276fbcb","volume":"126","author":"V Aboyans","year":"2012","unstructured":"Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126(24):2890\u2013909.","journal-title":"Circulation"},{"issue":"35","key":"3216_CR26","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33(35):4210\u20138.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03216-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03216-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03216-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T12:04:20Z","timestamp":1642334660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03216-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,11]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3216"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03216-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2021,9,11]]},"assertion":[{"value":"27 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}